| Dr Dipty Mangla, MD | |
|
776 E Providence Rd, Apartment D 309, Aldan, PA 19018 | |
| (732) 675-1923 | |
| Not Available |
| Full Name | Dr Dipty Mangla |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 16 Years |
| Location | 776 E Providence Rd, Aldan, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801124870 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Atlanticare Regional Medical Center | Atlantic city, NJ | Hospital |
| Entity Name | Atlanticare Physician Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093829608 PECOS PAC ID: 8527953660 Enrollment ID: O20040218000405 |
News Archive
An estimated 70–80% of ventilated patients will experience ICU delirium, which causes patients to enter a confused state and can lead to long-term cognitive impairments and memory deficits. GlobalData, therefore, expects to see an increase in the administration of pharmacological treatments for ICU delirium as the COVID-19 outbreak continues.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for malaria, HIV/AIDS, hepatitis, tuberculosis and detection, announced today the implementation of a program to accelerate the availability of the world's first Integrated Optical BioSensor (IOBS) platform. The Company is currently reviewing research and manufacturing partnerships to develop simple to replicate bench top versions of the IOBS platform on which single pathogen or multiple pathogen testing assay cartridges can be developed.
This proposed rule, which is required by the health law, outlines how Medicare will reward hospitals for delivering high-quality care.
CeloNova BioSciences, Inc. has received approval from its European regulatory body, the British Standards Institution, to expand the list of medical indications for which Embozene(TM) Microspheres may be used and to add a tenth size of the product.
› Verified 4 days ago
| Entity Name | Mainland Pain Management Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942918230 PECOS PAC ID: 2668843590 Enrollment ID: O20230131003635 |
News Archive
An estimated 70–80% of ventilated patients will experience ICU delirium, which causes patients to enter a confused state and can lead to long-term cognitive impairments and memory deficits. GlobalData, therefore, expects to see an increase in the administration of pharmacological treatments for ICU delirium as the COVID-19 outbreak continues.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for malaria, HIV/AIDS, hepatitis, tuberculosis and detection, announced today the implementation of a program to accelerate the availability of the world's first Integrated Optical BioSensor (IOBS) platform. The Company is currently reviewing research and manufacturing partnerships to develop simple to replicate bench top versions of the IOBS platform on which single pathogen or multiple pathogen testing assay cartridges can be developed.
This proposed rule, which is required by the health law, outlines how Medicare will reward hospitals for delivering high-quality care.
CeloNova BioSciences, Inc. has received approval from its European regulatory body, the British Standards Institution, to expand the list of medical indications for which Embozene(TM) Microspheres may be used and to add a tenth size of the product.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Dipty Mangla, MD 300 Shore Rd, Linwood, NJ 08221-2527 Ph: (267) 273-9083 | Dr Dipty Mangla, MD 776 E Providence Rd, Apartment D 309, Aldan, PA 19018 Ph: (732) 675-1923 |
News Archive
An estimated 70–80% of ventilated patients will experience ICU delirium, which causes patients to enter a confused state and can lead to long-term cognitive impairments and memory deficits. GlobalData, therefore, expects to see an increase in the administration of pharmacological treatments for ICU delirium as the COVID-19 outbreak continues.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for malaria, HIV/AIDS, hepatitis, tuberculosis and detection, announced today the implementation of a program to accelerate the availability of the world's first Integrated Optical BioSensor (IOBS) platform. The Company is currently reviewing research and manufacturing partnerships to develop simple to replicate bench top versions of the IOBS platform on which single pathogen or multiple pathogen testing assay cartridges can be developed.
This proposed rule, which is required by the health law, outlines how Medicare will reward hospitals for delivering high-quality care.
CeloNova BioSciences, Inc. has received approval from its European regulatory body, the British Standards Institution, to expand the list of medical indications for which Embozene(TM) Microspheres may be used and to add a tenth size of the product.
› Verified 4 days ago